Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

763 results about "Periodontal disease" patented technology

Edible compositions capable of removing oral biofilm

InactiveUS20050058744A1Significantly adsorbing oral bacteriaReduce bacterial adhesionCosmetic preparationsToilet preparationsDiseaseCarrageenan
An edible and/or chewable article of manufacture containing at least one food grade substance having adsorption affinity towards at least one dental plaque (biofilm) constituent and capable of reducing and/or removing the oral biofilm while present in the mouth. Particular articles of manufacture are chewing gums, sweets, candies, candy, and other nutritional bars, ice creams, chocolates, confectionery and bakery/pastry products, honey, dairy products and beverages, and oral hygiene products such as tooth pastes, oral gels and mouthwashes. A chewing gum having a conventional gum base and at least one food grade active substance having adsorption affinity towards at least one dental plaque (biofilm) constituent (bacteria and proteins and bacterial cell-free enzymes) and capable of reducing and/or removing the oral biofilm while present in the mouth. Active substances include polysaccharides and non-toxic salts thereof, such as alginates, chitosan, carboxymethylcellulose, agar and carrageenan, inorganic substances such as silica, hydroxyapatite and calcium carbonate and proteins, particularly gelatin and lectin. The article of manufacture removes and/or for prevents or reduces dental plaque (biofilm), and controlling oral, dental and periodontal diseases.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD

Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals

InactiveUS20080317885A1Salicyclic acid active ingredientsBiocideReactive airway diseaseSarcoidosis
Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.
Owner:BAKER DONALD J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products